Broadfoot Jill Marie 4
4 · aTYR PHARMA INC · Filed Feb 6, 2024
Insider Transaction Report
Form 4
aTYR PHARMA INCLIFE
Broadfoot Jill Marie
Chief Financial Officer
Transactions
- Exercise/Conversion
Restricted Stock Unit
2024-02-05−3,750→ 7,500 total→ Common Stock (3,750 underlying) - Sale
Common stock
2024-02-06$1.69/sh−1,590$2,687→ 20,821 total - Exercise/Conversion
Common stock
2024-02-05+3,750→ 22,411 total
Footnotes (4)
- [F1]Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
- [F2]Restricted stock units convert into common stock on a one-for-one basis.
- [F3]Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
- [F4]The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.